DrugPatentWatch Database Preview
Glaxosmithkline Company Profile
Email this page to a colleague
» See Plans and PricingUS Patents for Glaxosmithkline
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | NUCALA | mepolizumab | INJECTABLE;SUBCUTANEOUS | 761122 | 001 | 2019-06-06 | 10,028,940 | Knopp Biosciences LLC (Pittsburgh, PA) | 2033-08-13 | RX | search | |
| Glaxosmithkline | NUCALA | mepolizumab | INJECTABLE;SUBCUTANEOUS | 761122 | 001 | 2019-06-06 | 10,047,033 | DS BIOPHARMA LIMITED (Dublin, IE) | 2035-05-13 | RX | search | |
| Glaxosmithkline | NUCALA | mepolizumab | INJECTABLE;SUBCUTANEOUS | 761122 | 001 | 2019-06-06 | 10,111,968 | CureVac AG (Tubingen, DE) | 2032-02-15 | RX | search | |
| Glaxosmithkline | NUCALA | mepolizumab | INJECTABLE;SUBCUTANEOUS | 761122 | 001 | 2019-06-06 | 10,195,183 | Knopp Biosciences LLC (Pittsburgh, PA) | 2033-08-13 | RX | search | |
| Glaxosmithkline | NUCALA | mepolizumab | INJECTABLE;SUBCUTANEOUS | 761122 | 001 | 2019-06-06 | 10,195,211 | Patheon Softgels, Inc. (High Point, NC) | 2035-06-15 | RX | search | |
| Glaxosmithkline | NUCALA | mepolizumab | INJECTABLE;SUBCUTANEOUS | 761122 | 001 | 2019-06-06 | 10,231,976 | PRAIRIE PHARMACEUTICALS LLC (Bethesda, MD) | 2030-02-08 | RX | search | |
| Glaxosmithkline | NUCALA | mepolizumab | INJECTABLE;SUBCUTANEOUS | 761122 | 001 | 2019-06-06 | 10,273,252 | UBE INDUSTRIES, LTD. (Yamaguchi, JP) | 2036-04-28 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Similar Applicant Names
Companies are sometimes listed under multiple names.
This search can help find similar names.
This search can help find similar names.
